- Home
- TLS vs NGNE Comparison
TLS vs NGNE Comparison
Compare TLS & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- NGNE
- Stock Information
- Founded
- TLS 1969
- NGNE 2003
- Country
- TLS United States
- NGNE United States
- Employees
- TLS 519
- NGNE N/A
- Industry
- TLS EDP Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- TLS Technology
- NGNE Health Care
- Exchange
- TLS Nasdaq
- NGNE Nasdaq
- Market Cap
- TLS 209.4M
- NGNE 325.3M
- IPO Year
- TLS 2020
- NGNE N/A
- Fundamental
- Price
- TLS $2.73
- NGNE $22.79
- Analyst Decision
- TLS Buy
- NGNE Strong Buy
- Analyst Count
- TLS 6
- NGNE 7
- Target Price
- TLS $3.94
- NGNE $41.86
- AVG Volume (30 Days)
- TLS 673.5K
- NGNE 190.8K
- Earning Date
- TLS 08-08-2025
- NGNE 08-08-2025
- Dividend Yield
- TLS N/A
- NGNE N/A
- EPS Growth
- TLS N/A
- NGNE N/A
- EPS
- TLS N/A
- NGNE N/A
- Revenue
- TLS $109,269,000.00
- NGNE $925,000.00
- Revenue This Year
- TLS $35.76
- NGNE N/A
- Revenue Next Year
- TLS $26.83
- NGNE N/A
- P/E Ratio
- TLS N/A
- NGNE N/A
- Revenue Growth
- TLS N/A
- NGNE N/A
- 52 Week Low
- TLS $1.83
- NGNE $6.88
- 52 Week High
- TLS $4.82
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- TLS 44.26
- NGNE 50.72
- Support Level
- TLS $2.79
- NGNE $20.80
- Resistance Level
- TLS $2.93
- NGNE $23.88
- Average True Range (ATR)
- TLS 0.15
- NGNE 1.46
- MACD
- TLS -0.02
- NGNE -0.13
- Stochastic Oscillator
- TLS 14.29
- NGNE 26.18
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.